Maximizing the power of proteomic clinical trial profiling for better actionable insights - a new collaborative initiative from the SCALLOP consortium

Speakers: Anders Mälarstig, Direct of Target science at Pfizer

Original Broadcast date:  June 21 2021

Over the past 4 years, the SCALLOP consortium has conducted studies aimed at identifying correlative and causal protein biomarkers for common complex diseases. In the Nature Metabolism paper from 2020, it was shown that identification of protein quantitative trait loci (pQTL) for proteins measured with Olink PEA, followed by systematic Mendelian randomization analysis of common diseases was able to both validate known drug targets and generate novel target hypotheses.

To meet some key challenges in early phase clinical trials, SCALLOP is now aiming take the next step in protein biomarker research by building a new precompetitive collaboration, aimed at studying dynamic protein changes over time, and the role of pQTLs in determining protein trajectories, at scale. They have therefore taken the initial steps towards a data repository with Olink PEA proteomics data, basic clinical information and genetics from the placebo or standard of care arms of clinical trials.

The main points covered in the webinar are:

• How SCALLOP studies over the past 4 years have identified correlative and causal protein biomarkers for common complex diseases.
• How protein quantitative trait loci (pQTL) identified via proteogenomic studies, combined with systematic Mendelian randomization analysis, can identify novel drug targets based on confident assessment of causality in the diseases of interest
• A new clinical trial arm for SCALLOP, with a new precompetitive collaboration aimed at studying dynamic protein changes over time and increasing the statistical power of proteomic profiling data from phase I/II trials
• Understand the value of this collaborative approach in overcoming the challenges of small sample sizes in early clinical trials, enabling new insights into the mechanism of action, safety endpoints and response stratification for investigational new drugs

If you have any questions about Olink, please contact us at info@olink.com.